HSD17B7 Counters Bone Loss in Estrogen Deficiency via Estrogen Receptor Stabilization and Mediates the Effect of Raloxifene

Abstract

Estrogen receptor (ER) α is a central regulator of osteoclasts in osteoporosis induced by estrogen deficiency. ERα is regulated through interactions with various coactivators; however, the precise mechanisms of these interactions are not yet fully understood. We screened for proteins that bind to ERα using LC–MS/MS and identified a physical interaction between HSD17B7 and ERα, specifically ERα binding to the 119–172 domain of HSD17B7. This interaction blocked ubiquitin–proteasomal degradation of ERα and increased ERE activity. Estrogen-deficient mice lacking HSD17B7 in their preosteoclasts showed more severe bone loss than control mice. This was attributed to increased mitochondrial biogenesis through the activation of PLD1–mTOR signaling. Additionally, in preosteoclasts derived from patients with severe osteoporosis, the expression of HSD17B7 and ERα was significantly reduced compared to the control subjects. Finally, raloxifene, which boosts ERα, did not inhibit bone loss without HSD17B7, confirming the modulation of ERα through HSD17B7. Therefore, HSD17B7 regulation is a novel therapeutic approach for alleviating estrogen-deficient osteoporosis.

Keywords

estrogen receptor alpha / HSD17B7 / mitochondria / osteoporosis / raloxifene

References

[1] M. S. LeBoff, S. L. Greenspan, K. L. Insogna, et al., “The Clinician's Guide to Prevention and Treatment of Osteoporosis,” Osteoporosis International 33, no. 10 (2022): 2049–2102.

[2] G. D. Mishra, M. C. Davies, S. Hillman, et al., “Optimising Health After Early Menopause,” Lancet 403, no. 10430 (2024): 958–968.

[3] S. C. Manolagas, “The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go,” Journal of Bone and Mineral Research 33, no. 3 (2018): 371–385.

[4] J. N. Farr, M. Xu, M. M. Weivoda, et al., “Targeting Cellular Senescence Prevents Age-Related Bone Loss in Mice,” Nature Medicine 23, no. 11 (2017): 1072–1079.

[5] C. Song, A. Valeri, F. Song, et al., “Sexual Dimorphism of Osteoclast Reliance on Mitochondrial Oxidation of Energy Substrates in the Mouse,” JCI Insight 8, no. 24 (2023): 174293.

[6] T. Nakamura, Y. Imai, T. Matsumoto, et al., “Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts,” Cell 130, no. 5 (2007): 811–823.

[7] H. Kim, F. Ponte, I. Nookaew, et al., “Estrogens Decrease Osteoclast Number by Attenuating Mitochondria Oxidative Phosphorylation and ATP Production in Early Osteoclast Precursors,” Scientific Reports 10, no. 1 (2020): 11933.

[8] S. Bord, D. C. Ireland, S. R. Beavan, and J. E. Compston, “The Effects of Estrogen on Osteoprotegerin, RANKL, and Estrogen Receptor Expression in Human Osteoblasts,” Bone 32, no. 2 (2003): 136–141.

[9] N. K. Shevde, A. C. Bendixen, K. M. Dienger, and J. W. Pike, “Estrogens Suppress RANK Ligand-Induced Osteoclast Differentiation via a Stromal Cell Independent Mechanism Involving c-Jun Repression,” PNAS 97, no. 14 (2000): 7829–7834.

[10] S. Srivastava, M. N. Weitzmann, R. B. Kimble, et al., “Estrogen Blocks M-CSF Gene Expression and Osteoclast Formation by Regulating Phosphorylation of Egr-1 and Its Interaction With Sp-1,” Journal of Clinical Investigation 102, no. 10 (1998): 1850–1859.

[11] C. M. Mangione, M. J. Barry, W. K. Nicholson, et al., “Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement,” JAMA 328, no. 17 (2022): 1740–1746.

[12] C. Muschitz, R. Kocijan, A. Fahrleitner-Pammer, et al., “Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density—The Confors Study,” Journal of Bone and Mineral Research 29, no. 8 (2014): 1777–1785.

[13] R. K. Rej, J. E. Thomas, R. K. Acharyya, J. M. Rae, and S. Wang, “Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges,” Journal of Medicinal Chemistry 66, no. 13 (2023): 8339–8381.

[14] V. J. Armstrong, M. Muzylak, A. Sunters, et al., “Wnt/β-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-Bearing and Requires Estrogen Receptor α,” Journal of Biological Chemistry 282, no. 28 (2007): 20715–20727.

[15] J. I. Aguirre, L. I. Plotkin, A. R. Gortazar, et al., “A Novel Ligand-Independent Function of the Estrogen Receptor Is Essential for Osteocyte and Osteoblast Mechanotransduction,” Journal of Biological Chemistry 282, no. 35 (2007): 25501–25508.

[16] S. H. Windahl, L. Saxon, A. E. Börjesson, et al., “Estrogen Receptor-α Is Required for the Osteogenic Response to Mechanical Loading in a Ligand-Independent Manner Involving Its Activation Function 1 but Not 2,” Journal of Bone and Mineral Research 28, no. 2 (2013): 291–301.

[17] P. Ciana, M. Raviscioni, P. Mussi, et al., “In Vivo Imaging of Transcriptionally Active Estrogen Receptors,” Nature Medicine 9, no. 1 (2003): 82–86.

[18] A. Shehu, J. Mao, G. B. Gibori, et al., “Prolactin Receptor-Associated Protein/17β-Hydroxysteroid Dehydrogenase Type 7 Gene (HSD17B7) Plays a Crucial Role in Embryonic Development and Fetal Survival,” Molecular Endocrinology 22, no. 10 (2008): 2268–2277.

[19] A. Shehu, C. Albarracin, Y. S. Devi, et al., “The Stimulation of HSD17B7 Expression by Estradiol Provides a Powerful Feed-Forward Mechanism for Estradiol Biosynthesis in Breast Cancer Cells,” Molecular Endocrinology 25, no. 5 (2011): 754–766.

[20] X. Xu, B. Tassone, P. Ostano, et al., “HSD17B7 Gene in Self-Renewal and Oncogenicity of Keratinocytes From Black Versus White Populations,” EMBO Molecular Medicine 13, no. 7 (2021): e14133.

[21] Y. J. Moon, Z. Zhang, I. H. Bang, et al., “Sirtuin 6 in Preosteoclasts Suppresses Age- and Estrogen Deficiency-Related Bone Loss by Stabilizing Estrogen Receptor α,” Cell Death and Differentiation 26, no. 11 (2019): 2358–2370.

[22] H. Park, Y.-K. Jung, O.-J. Park, Y. J. Lee, J.-Y. Choi, and Y. Choi, “Interaction of Fas Ligand and Fas Expressed on Osteoclast Precursors Increases Osteoclastogenesis,” Journal of Immunology 175, no. 11 (2005): 7193–7201.

[23] X. Xia, Y. Liao, C. Huang, et al., “Deubiquitination and Stabilization of Estrogen Receptor α by Ubiquitin-Specific Protease 7 Promotes Breast Tumorigenesis,” Cancer Letters 465 (2019): 118–128.

[24] Q.-G. Zhang, D. Han, R.-M. Wang, et al., “C Terminus of Hsc70-Interacting Protein (CHIP)-Mediated Degradation of Hippocampal Estrogen Receptor-α and the Critical Period Hypothesis of Estrogen Neuroprotection,” PNAS 108, no. 35 (2011): E617–E624.

[25] H. Jokela, P. Rantakari, T. Lamminen, et al., “Hydroxysteroid (17β) Dehydrogenase 7 Activity Is Essential for Fetal De Novo Cholesterol Synthesis and for Neuroectodermal Survival and Cardiovascular Differentiation in Early Mouse Embryos,” Endocrinology 151, no. 4 (2010): 1884–1892.

[26] S. Aoki, K. Shimizu, and K. Ito, “Autophagy-Dependent Mitochondrial Function Regulates Osteoclast Differentiation and Maturation,” Biochemical and Biophysical Research Communications 527, no. 4 (2020): 874–880.

[27] W. Ling, K. Krager, K. K. Richardson, et al., “Mitochondrial Sirt3 Contributes to the Bone Loss Caused by Aging or Estrogen Deficiency,” JCI Insight 6, no. 10 (2021): e146728.

[28] H. J. Yoo, W. C. Hwang, and D. S. Min, “Targeting of Phospholipase d1 Ameliorates Collagen-Induced Arthritis via Modulation of Treg and Th17 Cell Imbalance and Suppression of Osteoclastogenesis,” International Journal of Molecular Sciences 21, no. 9 (2020): 1–18.

[29] Y. Wei, Y. J. Zhang, Y. Cai, and M. H. Xu, “The Role of Mitochondria in mTOR-Regulated Longevity,” Biological Reviews 90, no. 1 (2015): 167–181.

[30] Y. Fang, I.-H. Park, A.-L. Wu, et al., “PLD1 Regulates mTOR Signaling and Mediates Cdc42 Activation of S6K1,” Current Biology 13, no. 23 (2003): 2037–2044.

[31] S. F. Eisen and H. A. Brown, “Selective Estrogen Receptor (ER) Modulators Differentially Regulate Phospholipase D Catalytic Activity in ER-Negative Breast Cancer Cells,” Molecular Pharmacology 62, no. 4 (2002): 911–920.

[32] H. A. Brown, P. G. Thomas, and C. W. Lindsley, “Targeting Phospholipase D in Cancer, Infection and Neurodegenerative Disorders,” Nature Reviews Drug Discovery 16, no. 5 (2017): 351–367.

[33] N. Bhadouria, A. G. Berman, J. M. Wallace, and N. Holguin, “Raloxifene Stimulates Estrogen Signaling to Protect against Age- and Sex-Related Intervertebral Disc Degeneration in Mice,” Frontiers in Bioengineering and Biotechnology 10 (2022): 924918.

[34] M. A. García-Pérez, R. Noguera, R. del Val, I. Noguera, C. Hermenegildo, and A. Cano, “Comparative Effects of Estradiol, Raloxifene, and Genistein on the Uterus of Ovariectomized Mice,” Fertility and Sterility 86, no. 4 (2006): 1003–1005.

[35] V. Rossi, G. Bellastella, C. De Rosa, et al., “Raloxifene Induces Cell Death and Inhibits Proliferation Through Multiple Signaling Pathways in Prostate Cancer Cells Expressing Different Levels of Estrogen Receptorα and β,” Journal of Cellular Physiology 226, no. 5 (2011): 1334–1339.

[36] E. R. Martins-Maciel, L. B. Campos, C. L. Salgueiro-Pagadigorria, A. Bracht, and E. L. Ishii-Iwamoto, “Raloxifene Affects Fatty Acid Oxidation in Livers From Ovariectomized Rats by Acting as a Pro-Oxidant Agent,” Toxicology Letters 217, no. 1 (2013): 82–89.

[37] M. Martin-Millan, M. Almeida, E. Ambrogini, et al., “The Estrogen Receptor-α in Osteoclasts Mediates the Protective Effects of Estrogens on Cancellous but Not Cortical Bone,” Molecular Endocrinology 24, no. 2 (2010): 323–334.

[38] Q. Dai, F. Xie, Y. Han, et al., “Inactivation of Regulatory-Associated Protein of mTOR (Raptor)/Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice,” Journal of Biological Chemistry 292, no. 1 (2017): 196–204.

[39] Q. Zhang, D. Han, R. Wang, et al., “C Terminus of Hsc70-Interacting Protein (CHIP)-Mediated Degradation of Hippocampal Estrogen Receptor-α and the Critical Period Hypothesis of Estrogen Neuroprotection,” PNAS 108, no. 35 (2011): E617–E624.

[40] M. Anbalagan and B. G. Rowan, “Estrogen Receptor Alpha Phosphorylation and Its Functional Impact in human Breast Cancer,” Molecular and Cellular Endocrinology 418, no. pt 3 (2015): 264–272.

[41] T. Masaki, M. Habara, Y. Sato, et al., “Calcineurin Regulates the Stability and Activity of Estrogen Receptor α,” PNAS 118, no. 44 (2021): e2114258118.

[42] S. Ali and R. C. Coombes, “Endocrine-Responsive Breast Cancer and Strategies for Combating Resistance,” Nature Reviews Cancer 2, no. 2 (2002): 101–112.

[43] D. W. Kang, M. Park, H. Oh, et al., “Phospholipase D1 Has a Pivotal Role in Interleukin-1β-Driven Chronic Autoimmune Arthritis Through Regulation of NF-κB, Hypoxia-Inducible Factor 1α, and FoxO3a,” Molecular and Cellular Biology 33, no. 14 (2013): 2760–2772.

[44] M. Cai, J. He, J. Xiong, et al., “Phospholipase D1-Regulated Autophagy Supplies Free Fatty Acids to Counter Nutrient Stress in Cancer Cells,” Cell Death & Disease 7, no. 11 (2016): e2448.

[45] A. Ramanathan and S. L. Schreiber, “Direct Control of Mitochondrial Function by mTOR,” PNAS 106, no. 52 (2009): 22229–22232.

[46] F. J. Rosario, M. B. Gupta, L. Myatt, et al., “Mechanistic Target of Rapamycin Complex 1 Promotes the Expression of Genes Encoding Electron Transport Chain Proteins and Stimulates Oxidative Phosphorylation in Primary Human Trophoblast Cells by Regulating Mitochondrial Biogenesis,” Scientific Reports 9, no. 1 (2019): 246.

[47] A. J. Pagán, L. J. Lee, J. Edwards-Hicks, et al., “mTOR-Regulated Mitochondrial Metabolism Limits Mycobacterium-Induced Cytotoxicity,” Cell 185, no. 20 (2022): 3720–3738. e13.

[48] M. Gadiya, N. Mori, M. D. Cao, et al., “Phospholipase D1 and Choline Kinase-α Are Interactive Targets in Breast Cancer,” Cancer Biology & Therapy 15, no. 5 (2014): 593–601.

[49] J. M. Gozgit, B. T. Pentecost, S. A. Marconi, R. S. J. Ricketts-Loriaux, C. N. Otis, and K. F. Arcaro, “PLD1 is Overexpressed in an ER-Negative MCF-7 Cell Line Variant and a Subset of Phospho-Akt-Negative Breast Carcinomas,” British Journal of Cancer 97, no. 6 (2007): 809–817.

[50] M. Allegretti, M. C. Cesta, M. Zippoli, et al., “Repurposing the Estrogen Receptor Modulator Raloxifene to Treat SARS-CoV-2 Infection,” Cell Death and Differentiation 29, no. 1 (2022): 156–166.

[51] D. Tong, “Selective Estrogen Receptor Modulators Contribute to Prostate Cancer Treatment by Regulating the Tumor Immune Microenvironment,” Journal for ImmunoTherapy of Cancer 10, no. 4 (2022): e002944.

[52] C. C. Johnston, N. H. Bjarnason, F. J. Cohen, et al., “Long-Term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-Blind, Randomized, Placebo-Controlled Trials,” Archives of Internal Medicine 160, no. 22 (2000): 3444–3450.

[53] D. E. Jacobsen, R. J. F. Melis, H. J. J. Verhaar, and M. G. M. Olde Rikkert, “Raloxifene and Tibolone in Elderly Women: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial,” Journal of the American Medical Directors Association 13, no. 2 (2012): 189.e1–189.e2. e1897.

[54] X. Wang, C. Gérard, J.-F. Thériault, D. Poirier, C. J. Doillon, and S.-X. Lin, “Synergistic Control of Sex Hormones by 17β-HSD Type 7: A Novel Target for Estrogen-Dependent Breast Cancer,” Journal of Molecular Cell Biology 7, no. 6 (2015): 568–579.

[55] X. Dong, Y. Feng, D. Xu, et al., “Targeting Macrophagic 17β-HSD7 by Fenretinide for the Treatment of Nonalcoholic Fatty Liver Disease,” Acta Pharmacologica Sinica B 13, no. 1 (2023): 142–156.

[56] L. Qiang, L. Wang, N. Kon, et al., “Brown Remodeling of White Adipose Tissue by SirT1-Dependent Deacetylation of Pparγ,” Cell 150, no. 3 (2012): 620–632.

[57] E. S. Siris, R. Adler, J. Bilezikian, et al., “The Clinical Diagnosis of Osteoporosis: A Position Statement From the National Bone Health Alliance Working Group,” Osteoporosis International 25, no. 5 (2014): 1439–1443.

[58] P. M. Camacho, S. M. Petak, N. Binkley, et al., “American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update,” Endocrine Practice 26, no. suppl 1 (2020): 1–46.

[59] A. Porter, R. Irwin, J. Miller, D. J. Horan, A. G. Robling, and L. R. McCabe, “Quick and Inexpensive Paraffin-Embedding Method for Dynamic Bone Formation Analyses,” Scientific Reports 7 (2017): 42505.

[60] P. Wang, J. Zhang, J. Chen, et al., “Internal and External Co-Induction Pineal 3D Printed Scaffolds for Bone and Blood Vessel Regeneration,” Materials Today Advances 21 (2024): 100456.

[61] M. Song, C. Y. Han, Y. J. Moon, J. H. Lee, E. J. Bae, and B. Park, “Sirt6 Reprograms Myofibers to Oxidative Type Through CREB-Dependent Sox6 Suppression,” Nature Communications 13, no. 1 (2022): 1808.

[62] J. Lam, P. Katti, M. Biete, et al., “A Universal Approach to Analyzing Transmission Electron Microscopy With ImageJ,” Cells 10, no. 9 (2021): 2177.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.